Brief: OncoCyte Received Letter From Nasdaq Regarding Minimum Bid Price Requirement
15/08/2022 22:53
Aug 15 (Reuters) - OncoCyte Corp OCX.O :
* ONCOCYTE CORP - ON AUGUST 9, RECEIVED A LETTER FROM
NASDAQ
INDICATING NASDAQ DETERMINED THAT COMPANY NO LONGER MEETS
MINIMUM BID PRICE REQUIREMENT
Source text for Eikon: [https://bit.ly/3QKoPO9]
Further company coverage: OCX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Insight Molecular Diagnostics
See all newsBrief: Insight Molecular Diagnostics Enters Amendment No. 2 To Merger Agreement On Sept 15, 2026
Insight Molecular Diagnostics Inc reports results for the quarter ended June 30 - Earnings Summary
Insight Molecular Diagnostics Inc expected to post a loss of 24 cents a share - Earnings Preview
Insight Molecular Diagnostics Q1 loss narrows as costs drop
Brief: Insight Molecular Diagnostics Completes Key Milestones Advancing Graftassuredx Toward FDA Submission